EQS-News: Eckert & Ziegler with Significant Sales Growth in the First Nine Months of 2023
EQS-News: Eckert Ziegler Strahlen- und Medizintechnik AG
/ Key word(s): 9 Month figures
Berlin, 14 November 2023. Eckert Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, SDAX) achieved sales of € 183.9 million in the first nine months of 2023 (previous year: € 165.8 million) and consolidated net income of € 20.3 million (previous year: € 21.7 million). Adjusted for currency losses of € 3.3 million, the nine-month result was around € 2 million higher than the previous year's figure. In addition, there was an increase in expenses for future projects in the field of nuclear medicine diagnostics and therapy. The forecast for the financial year 2023 published on March 30, 2023 remains unchanged. The Executive Board continues to expect sales of around € 230 million and net income of around € 25 million. The complete quarterly report can be viewed here: About Eckert Ziegler.
14.11.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | Eckert Ziegler Strahlen- und Medizintechnik AG |
Robert-Rössle-Str.10 | |
13125 Berlin | |
Germany | |
Phone: | +49 30 941084-138 |
Fax: | +49 30 941084-112 |
E-mail: | [email protected] |
Internet: | www.ezag.de |
ISIN: | DE0005659700 |
WKN: | 565970 |
Indices: | SDAX, |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1772143 |
End of News | EQS News Service |
|
1772143 14.11.2023 CET/CEST
Eckert & Ziegler Strahlen- und Medizintechnik AG Stock
Eckert & Ziegler Strahlen- und Medizintechnik AG is currently one of the favorites of our community with 6 Buy predictions and no Sell predictions.
Based on the current price of 43.8 € the target price of 95 € shows a potential of 116.89% for Eckert & Ziegler Strahlen- und Medizintechnik AG which would more than double the current price.